RxDoctor Payments Data

Chloe Martin

Family · Johnsonville, SCNPI 1467992511

Payments from drug & device makers

$3,726in general payments, 2019–2025

Across 230 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$948
  • AstraZeneca$753
  • Novo Nordisk$427
  • Amgen$229
  • Abbott$159
  • Astellas Pharma US Inc$141
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,726100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,726 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,943
Medicare patients
16
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin123$123,118
FarxigaDapagliflozin Propanediol155$120,289
MounjaroTirzepatide60$62,579
EliquisApixaban49$46,118
JanuviaSitagliptin Phosphate53$42,300
OzempicSemaglutide30$31,590
XareltoRivaroxaban26$22,643
RybelsusSemaglutide12$15,635
LinzessLinaclotide18$13,374
Breo ElliptaFluticasone/Vilanterol23$10,046
Atorvastatin Calcium486$6,422
MyrbetriqMirabegron11$5,850
VascepaIcosapent Ethyl13$5,394
Mirabegron ErMirabegron11$4,934
Esomeprazole Magnesium42$3,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$82$123,118123 claims
AstraZenecaFarxiga$753$120,289155 claims
Lilly USA, LLCMounjaro$89$62,57960 claims
Novo NordiskOzempic, Rybelsus$427$47,22542 claims
PfizerEliquis$28$46,11849 claims
AbbVieLinzess, Synthroid$948$16,47085 claims
GSKBreo Ellipta$45$10,04623 claims
Astellas Pharma US IncMyrbetriq$141$5,85011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.

Other family in Johnsonville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →